Plain-English translation of NCT07138209 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a new medication called teclistamab to see if it works better than two standard treatment combinations ( with , or with ) for people with relapsed or refractory multiple myeloma — a blood cancer that has either returned after treatment or stopped responding to prior drugs. About 228 people will be randomly assigned to receive either the new medication alone or one of the two standard treatment combinations, and researchers will compare how well the medication works and how safe it is.
Multiple myeloma that comes back or stops responding to treatment is difficult to manage, and people with this advanced disease need new options. This trial exists to see whether this medication could offer better results or fewer side effects than the treatments currently available.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to either receive teclistamab as a single medication, or to receive one of the two standard treatment combinations chosen by your study doctor. You will have regular clinic visits for treatment, blood tests, and check-ups to monitor how well the medication is working and watch for any side effects. The exact schedule and length of the trial will be explained during the screening process.
AI-generated summary from trial data · Jun 25, 2026 · Not medical advice
China